Hajar Al Feteisi

TL;DR: Transporter abundances, taken together with the scaling factor, microvessel protein content per unit tissue, can be used in quantitative systems pharmacology models predicting drug disposition in the brain and permitting dose adjustment (precision dosing) in special populations of patients, such as those with dementia.

TL;DR: Rigorous quantification of BBB proteins, as reported in this study, should assist with translational modeling efforts involving brain disposition of xenobiotics.

TL;DR: The first use of ion mobility–mass spectrometry for this purpose is reported, allowing rapid, robust, label-free quantification of human liver microsomal (HLM) proteins from distinct individuals, showing, for the first time, that HLMs are significantly heterogeneous.

TL;DR: A cost-benefit approach is described to assess the most appropriate mass spectrometry-based approach for the quantification of proteins relevant to IVIVE and to present a framework to objectively assess the choice of the techniques.

TL;DR: This report presents an overview of mass spectrometry-based methods currently used for the quantification of drug-metabolizing enzymes and drug transporters, mainly focusing on applications and cost associated with various quantitative strategies based on stable isotope-labeled standards (absolute quantification peptide standards, quantification concatemers, protein standards for absolute quantification) and label-free analysis.